Gyno Daktarin

Quick links

Choose a section

Quick links to important sections

Advertisements

Gyno Daktarin

Advertisements
Advertisements

Overview of Gyno Daktarin

Quick Facts

Property Description
Active ingredient Miconazole Nitrate
Form Vaginal Ovule, Vaginal Cream
Pharmacological class Azole Antifungal, Antimycotic
Common use Resolution of local fungal infections
Origin Synthetic (Imidazole derivative)

What is the Pharmacological Class of Gyno Daktarin?

Gyno Daktarin is a brand-name medicinal preparation centered on the active substance Miconazole Nitrate, which is classified as a synthetic Antifungal Agent. Miconazole Nitrate is an imidazole derivative, positioning it within the well-recognized azole antifungal class of medications. It is recognized for its potent action against fungal organisms, predominantly Candida species. This classification indicates the drug's specialized function, as it is designed specifically for addressing vulvovaginal yeast infections, a typical scenario for its use.

What is Miconazole Nitrate and How is it Administered?

The preparation is a single-ingredient product focused on Miconazole Nitrate, which is formulated for targeted, local application. Gyno Daktarin is commonly available as a Vaginal Ovule and a Vaginal Cream, both engineered for direct vaginal administration. This differentiation of dosage forms ensures the ability to tailor delivery based on patient preference and the specific needs of the local tissue. For instance, the ovule utilizes a waxy base designed to melt at body temperature, contrasting with the emulsion vehicle used in the cream, providing flexibility in how the active component is delivered.

How Does Gyno Daktarin Generally Resolve Fungal Infections?

The general purpose of this preparation is to resolve localized fungal infections by employing a specific biochemical strategy. Miconazole Nitrate acts by interfering with the structure of the fungal cell membrane; it disrupts the biosynthesis of ergosterol, a structural lipid essential for the cell's integrity. This targeted action compromises the fungal cell, resulting in an effect that is both fungistatic (inhibiting proliferation) and potentially fungicidal (destroying the organism). This direct anti-fungal action is the basis for the drug's intended benefit: eliminating the source of the fungal overgrowth.

Regulatory References

  1. Miconazole action mechanism (NIH)
Advertisements

What side effects are possible with Gyno Daktarin?

Possible Side Effects and Safety Information

The safety profile of Miconazole Nitrate (the active ingredient in Gyno Daktarin) is primarily characterized by adverse reactions occurring at the site of local application. These reactions are classified by regulatory authorities based on their frequency in clinical use.


Officially Documented Adverse Reactions

Frequency Category System-Organ Class Examples of Reactions
Common Reproductive System, General Disorders, Nervous System Vulvovaginal burning sensation, vulvovaginal pruritus (itching), headache, application site irritation.
Uncommon Reproductive System Pelvic pain, vulvovaginal discomfort.
Not Known Immune System, Skin and Subcutaneous Tissue Hypersensitivity, Anaphylactic reaction, Angioedema.

Safety Considerations and Restrictions

Serious Adverse Reactions officially documented include rare, severe immune-related events such as Anaphylactic reactions and Angioedema. These are classified under the Immune System Disorders and require immediate consideration.

Local adverse effects, such as burning or irritation, may be more noticeable at the start of treatment and often diminish as therapy progresses. Regulatory documents advise treatment discontinuation if significant irritation or signs of sensitization occur.

Safety Restrictions include a contraindication for individuals with a known hypersensitivity to Miconazole, to other imidazole derivatives, or to any component of the formulation. Caution is explicitly required when using this medication concurrently with certain oral anticoagulants, such as Warfarin, due to the potential for drug-drug interaction that may enhance the anticoagulant effect.

Population-Specific Safety notes advise that use during Pregnancy, particularly the first trimester, should only proceed if the prescribing physician deems it essential. Caution is also advised during Lactation due to the minimal but acknowledged systemic absorption.

Advertisements

Overdose and Emergency Response

Overdose from the intended use of Miconazole Nitrate vaginal ovules or cream is officially considered unlikely due to limited systemic absorption through the vaginal mucosa. Regulatory documents do not contain reports of specific symptoms related to overdosage from the approved topical or intravaginal application.

The main scenario that requires urgent attention is the accidental oral ingestion of the product, particularly when consumed in large quantities. In this event, potential clinical manifestations may include gastrointestinal disturbances such as vomiting and diarrhoea. If the product is swallowed, the mandated emergency action is to seek immediate professional medical help by contacting a Poison Control Center or emergency services right away.

Treatment for accidental ingestion is limited to symptomatic and appropriate supportive care, as there is no specific antidote documented in official labeling. A specific caution is noted for patients taking the anticoagulant warfarin; due to the potential for a severe drug interaction following accidental systemic exposure, careful monitoring of the patient’s anticoagulation status is a required element of clinical management.

Advertisements

Therapeutic Uses of Gyno Daktarin

What Gyno Daktarin Treats: Main Uses and Benefits

The medication is commonly used in therapeutic domains relevant to women's health and applied across domains where additional symptomatic support is needed, specifically addressing symptoms associated with fungal overgrowth. It is relevant in contexts involving heightened systemic burden and used in settings where short-term symptomatic assistance is appropriate for acute episodes of discomfort.

This medication is commonly used in conditions characterized by periods of heightened symptoms, such as vulvovaginal candidiasis (thrush). The relevant areas of use include managing the symptoms related to yeast infections, providing relief from symptoms related to intense localized itching and burning, and assisting with symptoms related to abnormal discharge and associated inflammation. This supportive approach may help patients cope more steadily with difficult episodes.

This medication helps address symptom clusters that may appear suddenly and create noticeable interference with daily stability. It is used in situations involving symptomatic discomfort and applied in scenarios where additional management of discomfort of the vulvovaginal area is required, helping to reduce the overall burden of visible and distressing manifestations.

Quick Fact: Relief for Localized Discomfort Gyno-Daktarin supports the management of acute symptoms that interfere with comfort, such as the itching and burning sensation linked to fungal overgrowth.

Regulatory References

  1. NIH MedlinePlus overview of Miconazole Vaginal
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gyno Daktarin — official regulatory information

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults (typically 18 years and older) without contraindications or restricting symptoms.
Populations for whom use is not recommended (if applicable) Children under 12 years of age are generally instructed to ask a doctor, as use is not established in this population.
Populations for whom use is contraindicated Individuals with known hypersensitivity to Miconazole, Miconazole Nitrate, other imidazole derivatives, or any other component of the product.
Age-related eligibility rules Pediatric use (under 12 years) is not established. Adults and adolescents 12 years and older are generally eligible, depending on the specific formulation.
Condition-specific eligibility rules Patients with accompanying systemic symptoms such as fever, chills, abdominal pain, or foul-smelling discharge must consult a health professional prior to use.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: Use in the first trimester should only occur if a physician determines the potential benefits outweigh the possible risks. Lactation: Caution should be exercised during use.
Eligibility-related restrictions Concomitant local use: The product must not be used concurrently with latex barrier contraceptives (condoms or diaphragms). Drug Co-administration: Patients on oral anticoagulants (e.g., Warfarin) must use the product with caution and require monitoring.

Eligibility Classifications (High-Level)

Category Classification Details
Eligibility severity classification (as defined in official documents) Absolute Contraindication: Hypersensitivity to ingredients. Conditional Use/Caution: Pregnancy, breastfeeding, use with oral anticoagulants, and use with latex contraceptives.
Regulatory basis (EMA / FDA / etc.) Based on Summaries of Product Characteristics (SmPC) from European/national agencies and FDA prescribing information.
Eligibility-context constraints (as defined in official documents) Eligibility is limited by local product interactions (latex contraceptives) and the presence of systemic 'red flag' symptoms (fever, pain).

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use Gyno Daktarin by establishing criteria rooted in the drug's composition and method of use. The primary exclusions are absolute contraindications for ingredient hypersensitivity and a necessary prohibition on co-administration with latex contraceptives. Conditional use rules restrict eligibility based on age, pre-existing symptoms, concomitant medications, and physiological states, reflecting situations where a physician must assess the overall profile.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Although Gyno Daktarin (miconazole) is applied to the vagina and has only limited systemic absorption into the bloodstream, it is essential to be aware of potential drug interactions. Clinically significant interactions occur very rarely with this form of miconazole. However, caution is required, particularly with medicines that have a narrow therapeutic index.

Miconazole is known to inhibit certain liver enzymes (CYP3A4 and CYP2C9) which are responsible for breaking down many other medications. This mechanism, even with limited absorption, could potentially increase the levels and effects of co-administered drugs.

Interacting Medicinal Product Categories:

  • Oral Anticoagulants (Blood Thinners): The effect of medicines like warfarin may be increased, leading to a risk of bleeding. If you are taking oral anticoagulants, your blood-thinning effect must be monitored closely if you use this product.
  • Oral Hypoglycemics: The effects and side effects of drugs like phenytoin (for seizures) and oral hypoglycemics (for diabetes) may be increased. Exercise caution with these combinations.

Non-Systemic Product Interaction:

  • Latex Contraceptives: The use of latex condoms or diaphragms must be avoided during and for a period after treatment. Components in the vaginal product may damage the latex, which could cause the contraceptive method to fail.
Advertisements

Mechanism of Action

Targeted Inhibition of Fungal Enzyme Activity

The mechanism of Gyno Daktarin, utilizing Miconazole Nitrate, is defined by a specific biochemical interaction on the structural integrity and metabolic processes exclusive to fungal organisms. The drug acts as an inhibitor of the fungal enzyme 14alpha-demethylase ( CYP51). The Miconazole molecule binds to the enzyme's active site, arresting its function, which immediately blocks the subsequent steps of the fungal sterol biosynthesis pathway.


Disruption of Fungal Cell Membrane Integrity

The enzyme blockade causes a critical defect: the depletion of ergosterol, the fundamental structural lipid of the fungal cell membrane, and the subsequent accumulation of toxic sterol intermediates. This faulty lipid composition destabilizes the cell membrane, resulting in increased permeability and the uncontrolled leakage of essential cellular components.


Cascade Leading to Fungistatic and Fungicidal Effects

The resulting structural failure leads to the cessation of growth (fungistatic action). The extent of the damage can transition to a fungicidal effect (cell death) , as the cell can no longer maintain its internal environment or conduct vital metabolic functions, which results in the physical disintegration of the fungal organism.

Advertisements

Dosage and Administration Information

How Gyno Daktarin is Used: Official Administration Guidelines

Instructions for the use of Gyno Daktarin (Miconazole Nitrate) define its administration as a localized therapy. The medication is administered via the intravaginal route using ovules or cream, and the cream is also approved for topical application to the external vulvar area.

Official Administration Regimens

Administration is structured around fixed-duration courses, with specific instructions for dosing and frequency:

Therapy Duration Dosage Form Dosing Frequency
1-Day 1200 mg Suppository Once at bedtime
3-Day 200 mg Suppository or 4% Cream Once daily at bedtime for 3 days
7-Day 100 mg Suppository or 2% Cream Once daily at bedtime for 7 days

Procedural and Timing Instructions

Administration is typically advised to occur once daily at bedtime to maximize drug retention and local effectiveness. When using the vaginal cream, a provided applicator is required to measure and insert the correct dose deeply into the vagina. For external vulvar symptoms, the cream may be applied twice a day.

Course Completion and Special Rules

It is standard for the full course of treatment to be completed for the entire prescribed duration (1, 3, or 7 days), even if symptoms subside sooner. Furthermore, guidelines indicate to continue the full course during menstruation. The product is for local application only and is not to be swallowed. Use in children under 12 years of age is not established and requires medical consultation.

Advertisements

Recent Clinical Evidence

Gyno Daktarin: Recent Clinical Evidence

The clinical research base for Miconazole Nitrate is established by numerous Randomized Controlled Trials (RCTs) and systematic reviews spanning several decades of study. The evidence primarily focuses on the active substance in research settings for vulvovaginal candidiasis (thrush).


Evidence for Use in Vulvovaginal Candidiasis (Thrush)

Pivotal clinical studies were evaluated in adult women, conducted primarily as RCTs to assess Miconazole formulations against placebo or other approved antifungal treatments. Researchers examined comparisons between different short-term treatment schedules and formulations (e.g., vaginal cream versus ovule). The research explored several specific measurements, including assessments related to the status of the Candida organism (mycological assessment endpoint) and the status of physical signs and patient-reported discomfort (clinical assessment endpoint). Key measurements studied included the Overall Therapeutic Assessment Endpoint, a composite score requiring positive results across both clinical and laboratory assessments.


Long-Term Studies and Follow-up

Research typically observed patient responses over defined time intervals. Initial assessments were commonly conducted at a return visit around 7 to 11 days post-treatment. Intermediate-term follow-up occurred around 30 to 37 days post-treatment to monitor patterns of recurrence. These later assessments contribute to understanding the patterns following the initial observation period. However, long-term outcomes are not fully established, and there is limited information for outcomes tracked across multiple months or a full year.


Evidence in Special Populations and Uncertainties

Specific research was evaluated in certain patient groups, including dedicated studies examining pregnant women with confirmed vaginal candidiasis. The research primarily focuses on outcomes related to the most common strain, Candida albicans. Data for infections caused by certain non-Candida albicans species remains insufficient in comparison to the primary focus organism. Furthermore, the large-scale RCTs often excluded patients with specific complex conditions, such as those with diabetes, meaning data for certain groups remain insufficient.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gyno Daktarin (FAQ)


Q: How quickly does Gyno Daktarin start working for thrush?

Clinical studies often report that the median time to symptom relief (such as itching and irritation) is approximately four days. The full therapeutic response is typically assessed in clinical trials after the completion of the prescribed treatment duration (e.g., 3-day or 7-day courses).


Q: What is the risk of the yeast infection coming back after using Gyno Daktarin?

Regulatory-reviewed clinical studies monitor for the pattern of recurrence, with follow-up assessments often conducted about 30 to 37 days following the end of treatment. Official product labeling, however, does not typically provide a single, fixed percentage for the risk of recurrence, as this can vary individually.


Q: Can men use Gyno Daktarin to treat a yeast infection on the penis?

The Gyno Daktarin product is indicated for the vulvovaginal area. However, the active ingredient, Miconazole Nitrate, is commonly found in topical creams approved for fungal infections of the skin, including male thrush. Any application outside of the labeled vulvovaginal area should be discussed with a healthcare professional.


Q: Why do doctors often suggest treating the partner as well when using Gyno Daktarin?

Official patient information leaflets sometimes mention the importance of treating a sexual partner. This is related to the goal of preventing potential transmission and recurrence of the infection during and after the treatment period.


Q: Is Gyno Daktarin an over-the-counter medicine in some countries?

The active ingredient, Miconazole Nitrate, is available globally in various formulations as both a prescription drug and an over-the-counter (OTC) medicine. The specific availability and required dosage strength are dependent on the regulatory status in each country.


Q: Does Gyno Daktarin have a smell or noticeable scent?

Official documentation describes the product's appearance and lists all its inactive ingredients (excipients). However, regulatory product documents do not typically include information about whether the final product has a noticeable odor or scent.


Q: Does Gyno Daktarin cream stain clothing or bedding?

The components of the cream are not generally known to cause permanent stains. However, due to the nature of the medication, leakage from the vagina is common. Some patient information for Miconazole products notes that using a sanitary towel can help manage potential leakage onto clothing or bedding.


Q: Are there any specific lifestyle changes recommended while using Gyno Daktarin?

Regulatory patient information often suggests measures intended to prevent reinfection while using the product. These may include ensuring proper hygiene for the affected area and changing clothing that contacts the area.


Q: Are there any foods or drinks that can interact with Gyno Daktarin?

Official drug labeling focuses on potential interactions with specific oral medications (such as blood thinners) and certain devices (such as latex contraceptives). Regulatory documents do not typically list interactions with specific foods or beverages for Gyno Daktarin.


Q: Why are people sometimes prescribed a one-day treatment versus a seven-day course of Gyno Daktarin?

Clinical trials for Miconazole Nitrate have indicated that the higher strength one-day and three-day courses are considered statistically equivalent in efficacy to the lower-strength seven-day course. This allows for different regimens to be used based on clinical assessment and patient compliance needs.


Q: What is the purpose of the applicator that comes with Gyno Daktarin cream?

The applicator is provided as part of the product to help deliver the correct, measured dose of cream deeply into the vagina, as required by the official instructions for use.


Q: Can Gyno Daktarin make me feel dizzy or drowsy?

Common side effects documented in clinical use include headache. Other central nervous system effects, such as dizziness or drowsiness, are generally not listed as common or uncommon adverse reactions in the local product labeling.


Q: Is it normal to see some white discharge after inserting the Gyno Daktarin pessary?

Due to the nature of the vaginal ovule (pessary) base, which melts inside the body, the product components can result in a noticeable discharge or leakage from the vagina. This is a common occurrence noted in patient information.


Q: What components of Gyno Daktarin might cause an allergic reaction?

The product is officially contraindicated for those with known hypersensitivity to the active ingredient, Miconazole Nitrate, or to other imidazole derivatives. Official documentation also states that the product is contraindicated for those sensitive to any of the inactive ingredients (excipients) in the formulation.


Q: Is Gyno Daktarin available under a generic name?

Gyno Daktarin is a brand name. The medicine's active component is Miconazole Nitrate, which is the generic name and is widely available in formulations produced by many different manufacturers.


Q: What is the success rate of Gyno Daktarin in treating vulvovaginal candidiasis?

Clinical trials reviewed by regulatory bodies have reported the overall therapeutic cure rate for Miconazole Nitrate formulations (based on both clinical and mycological results) to be typically in the range of 58% to 69%, depending on the specific study and treatment course.


Q: Can Gyno Daktarin be used for a recurring yeast infection?

While standard courses are for initial infections, clinical guidelines sometimes include Miconazole in recommendations for the treatment of recurrent episodes of vulvovaginal candidiasis. The management of recurring infections requires assessment by a healthcare professional.


Q: Are there any long-term effects from repeated use of Gyno Daktarin?

Clinical trials primarily focus on short- to intermediate-term follow-up, tracking patient responses up to about 37 days after treatment. Official prescribing information states there is limited information available for patient outcomes tracked across multiple months or a full year.


Q: What does Gyno Daktarin treat specifically in the vagina?

Gyno Daktarin is specifically indicated for the local treatment of vulvovaginal candidiasis, which is the medical term for a vaginal yeast or thrush infection. This infection is predominantly caused by an overgrowth of Candida species.


Q: Can Gyno Daktarin treat bacterial vaginosis instead of a yeast infection?

Gyno Daktarin is classified and indicated as an antifungal medication, meaning its action is targeted against fungal infections (candidiasis). It is not indicated for the treatment of bacterial vaginosis (BV), a condition caused by a shift in vaginal bacteria.


Q: Are there any alternatives to Gyno Daktarin for women who cannot use pessaries?

The medication is available in different dosage forms. For patients who cannot use the vaginal ovule (pessary), the medicine is also formulated as a vaginal cream, which can be inserted using an applicator and applied externally.


Q: Can I use Gyno Daktarin if I have a history of liver issues?

Although the active ingredient is absorbed into the bloodstream only minimally, it is known to interact with certain liver enzymes (CYP3A4 and CYP2C9). Use with caution is therefore advised, especially if taking co-administered drugs that rely on these enzymes for metabolism. Such use requires careful consideration by a healthcare professional.


Q: What are the ingredients in the Gyno Daktarin cream besides the active component?

The cream contains the active ingredient Miconazole Nitrate, along with several inactive ingredients (excipients). These components include water, mineral oils, specific stabilizing agents, and commonly used preservatives such as Benzoic acid and Butylated hydroxyanisole.


Q: How is the active ingredient in Gyno Daktarin absorbed by the body?

The product is designed for targeted, local application at the site of infection. Official regulatory documents confirm that the active ingredient is absorbed into the general bloodstream only to a minimal degree (limited systemic absorption).


Q: What should I do if I forget a dose of Gyno Daktarin?

Patient information generally advises that if a dose is missed, it should not be applied later. Instead, the user should apply the next dose at the usual scheduled time and continue the treatment until the full course is completed.

Advertisements

How should Gyno Daktarin be stored and disposed of?

How to Store and Dispose of Gyno Daktarin?

The storage and disposal of this medicine are defined by official regulatory guidelines to maintain product stability and protect the environment. The instructions below are derived exclusively from the product’s labeled prescribing information.

Storage Component Official Requirement
Temperature Store at controlled room temperature, typically below 25 C or 30 C (check specific packaging). Do not freeze and avoid excessive heat.
Protection Keep the medicine out of the sight and reach of children. Store in the original packaging to protect from moisture and light.
Stability Do not use the medicine after the expiry date printed on the carton. The container must remain tightly closed and intact.
Disposal Do not throw away unused or expired medicine via wastewater or common household waste. Dispose of the product strictly according to local regulatory requirements for waste medicine collection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gyno Daktarin found in:

A-Z Index: